Author + information
- S1936879815020592-80dd3d5e1f42525072b8fa8df20c16f9Min-Ho Lee1,
- S1936879815020592-83e45353357d710a9dde9c5071cfa225Seung-Woon Rha2,
- S1936879815020592-22d3825c87bb8d7bec0721f6c825fd2dByung Won Park1,
- S1936879815020592-f8ca11ff5aa9a139a98de187281fbf14Duk Won Bang1,
- S1936879815020592-ee4e087cdbd32138eac14b6a58a69293Min Su Hyon1,
- S1936879815020592-38f9379288aee4a50a9131fa84c4a249Byoung Geol Choi2,
- S1936879815020592-53b75c6df57ff3836114113292e7ed5aSangho Park3,
- S1936879815020592-3d19c019d095c759f15a37f0a3eae3ecJihoon Ahn4 and
- S1936879815020592-2c7637807d41347deaf1951130df7e8bDong Joo Oh2
Reopro® (abciximab) is the Fab fragment of the chimeric human monoclonal antibody 7E3. Clotinab™ (abciximab) was produced by inserting anti-platelet glycoprotein (GP) IIb/IIIa DNA into a Chinese hamster’s ovary cell and is expected to have same efficacy with Reopro®. Although the increasing use of intravenous GP IIb/IIIa receptor blocker in the treatment of acute myocardial infarction (AMI) to reduce the risk of ischemic complications, there is a paucity of data on the differences in clinical outcomes between Clotinab™ and ReoPro® in AMI patients (pts) undergoing percutaneous coronary intervention (PCI).
Among 12,431 pts enrolled in the Korea AMI Registry (KAMIR) from July 2012, eligible 1,314 pts used GP IIb/IIIa receptor blockers were classified into two groups; 1) Clotinab™ group (n = 1,016) and 2) ReoPro® group (n = 298). Primary endpoint was major adverse cardiovascular events (MACE) defined as the composite of total death (TD), myocardial infarction (MI), and target vessel revascularization (TVR).
Clotinab™ group showed higher prevalence of dyslipidemia and lower prevalence of previous MI and multi-vessel disease than ReoPro® group. At 1 year, the incidence of MACE did not differ between Clotinab™ and ReoPro® group (9.4% vs. 9.7%, p = 0.822) in crude population. Also, in 3:1 propensity-score matched analysis, there was no significant difference in the incidence of MACE between the two groups (8.8% vs. 9.9%, p = 0.522). Individual major clinical outcomes including TD, MI, and TVR, no differences were observed between the two groups in both crude and matched population.
Clotinab™ was associated with similarly favorable 1-year clinical outcomes that were comparable to ReoPro® for AMI pts undergoing PCI in a series of large Asian AMI population.